Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Size Forecast 2024 - 2033
23 Dec, 2024
What Is The Scope Of The Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Chlamydia trachomatis (CT) and Neisseria gonorrhea (NG) testing refers to the procedure for diagnosing sexually transmitted infections (STIs) brought on by Neisseria gonorrhea (NG) and chlamydia trachomatis (CT) within sexually active individuals, especially if they have multiple partners or engage in unprotected sexual activity. These tests are conducted to detect the presence of these bacteria in individuals, typically through methods such as urine samples, swabs of genital areas, or blood tests.
Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2024 provides data on the global chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The chlamydia trachomatis (ct) and neisseria gonorrhoeae (ng) testing market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.
How Is The Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) TestingMarket Expected To Grow In Size And Annual Rates?
The market for chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing has grown considerably, from $1.79 billion in 2023 to $1.98 billion in 2024, reflecting a CAGR of 10.7%. Growth in prior years was driven by factors such as antibiotic resistance, public awareness campaigns, and policy changes. The market is set to grow further to $3.00 billion by 2028 at a CAGR of 11.0%, propelled by the adoption of telemedicine, personalized medicine approaches, expanded point-of-care testing, and strategies for population health management. Key trends include the expansion of rapid point-of-care testing, development of multi-disease testing platforms, personalized testing methods, and increased community-based testing initiatives.
What Main Forces Are Fueling Expansion In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The rise in sexually transmitted infections (STIs) is expected to drive the growth of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market. STIs are diseases caused by pathogens that are transmitted through sexual contact. The increase in STI rates is attributed to factors like inadequate sex education, higher sexual activity, and social stigma. CT and NG testing is crucial for detecting and managing STIs, enabling early diagnosis and prevention of further transmission. For instance, the World Health Organization reported in July 2023 that more than 1 million STIs are acquired daily worldwide, with an estimated 374 million new infections occurring each year. As a result, the growing number of STIs is driving the growth of the CTNG testing market.
Get Your Free Sample of the Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market ReportWhat Are The Primary Segments In The Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
The chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing market covered in this report is segmented –
1) By Test Type: Laboratory, Point Of Care Testing
2) By Product: Assays And Kits, Instruments Or Analyzers
3) By Technology: Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies
4) By End User: Diagnostic Laboratories, Hospitals And Clinics, Other End Users
Which Key Trends Are Driving Changes In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
Companies in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are developing innovative solutions like the BD COR MX/PX System to provide efficient, scalable, and accurate testing methods. BD COR MX/PX System is a high-throughput infectious disease molecular diagnostic platform designed for large-scale testing. For example, in May 2022, Becton Dickinson and Company, a US-based medical device firm, launched the BD COR MX/PX System. This fully automated system streamlines the workflow in large labs and processes a variety of infectious disease tests, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG). It features high-throughput capability, automation, dual DNA targets, and a modular, scalable design that improves efficiency and reduces wait times.
What Is The Leading Region In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market?
North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2023. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.